Lys161
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys161  -  p21Cip1 (human)

Site Information
kRrLIFSkRkP____   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 12615906

In vivo Characterization
Methods used to characterize site in vivo:
[14C] acetate labeling ( 1 ) , immunoassay ( 1 ) , immunoprecipitation ( 2 ) , mass spectrometry ( 1 ) , modification-specific antibody ( 2 ) , mutation of modification site ( 1 ) , western blotting ( 1 , 2 )
Disease tissue studied:
bone cancer ( 1 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 ) , liver cancer ( 1 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
siRNA ( 1 , 2 ) , trichostatin_A ( 2 )

Downstream Regulation
Effects of modification on p21Cip1:
molecular association, regulation ( 2 ) , protein stabilization ( 1 , 2 )
Effects of modification on biological processes:
carcinogenesis, inhibited ( 2 ) , cell cycle regulation ( 1 , 2 ) , cell growth, inhibited ( 1 , 2 )
Inhibit interaction with:
C8A (human) ( 2 )

References 

1

Lee MS, et al. (2013) Stabilization of p21 (Cip1/WAF1) following Tip60-dependent acetylation is required for p21-mediated DNA damage response. Cell Death Differ 20, 620-9
23238566   Curated Info

2

Li Z, et al. (2010) An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis. Oncogene 29, 2659-71
20154723   Curated Info